2023 was a troublesome calendar year for the biopharma business, with quite a few corporations downsizing and restructuring their workforces to stay afloat. You can find signs of Restoration, as mergers and acquisitions picked up throughout the pharmaceutical and daily life sciences sector while in the latter Portion of 2023 https://sites.google.com/view/bio-sites/blog